LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the presentation of new data supporting the use of Orthofix’s proprietary Pulsed Electromagnetic Field (PEMF) stimulation to increase fusion rates as an adjunct to lumbar spine fusion surgery.

德克萨斯州刘易斯维尔——（商业新闻短讯）——全球领先的医疗技术公司Orthofix Medical Inc.（纳斯达克：OFIX）今天宣布发布新数据，支持使用Orthofix专有的脉冲电磁场（PEMF）刺激来提高融合率，作为腰椎融合手术的辅助手段。

Patients treated with the SpinalStim™ bone growth therapy device demonstrated a high rate of successful fusion with significant improvements in pain, function and quality of life, despite having risk factors for pseudarthrosis..

尽管存在假性关节炎的危险因素，但使用SpinalStim™骨生长治疗仪治疗的患者融合成功率高，疼痛，功能和生活质量显着改善。。

The abstract will be presented by Dr. Marc Weinstein, an orthopedic spine surgeon at the Florida Orthopaedic Institute in Tampa, Florida, at the North American Spine Society (NASS) Annual Meeting in Chicago, IL, on September 25, during the Research and Innovation Showcase in the McCormick Place West Lobby of the McCormick Convention Center..

该摘要将于9月25日在伊利诺伊州芝加哥举行的北美脊柱协会（NASS）年会上，由佛罗里达州坦帕市佛罗里达骨科研究所的整形外科医生马克·温斯坦博士在麦考密克会议中心麦考密克广场西大厅的研究与创新展示会上发表。。

During the NASS annual meeting, Orthofix is also highlighting a variety of new products including the full market launch of OsteoStrand™ Plus C. A 100% bone-derived graft, OsteoStrand Plus C is comprised of Demineralized Bone Matrix (DBM) fibers and Accell™ Bone Matrix, a dispersed form of DBM that provides immediate release of growth factors upon implantation and increases the concentration of growth factors in the product, and cancellous chips.

在NASS年会期间，Orthofix还重点介绍了各种新产品，包括OsteoStrand™Plus C的全面上市。OsteoStrand Plus C是一种100%骨衍生移植物，由脱矿骨基质（DBM）纤维和Accell™骨基质（一种DBM的分散形式，可在植入后立即释放生长因子，并增加产品中生长因子的浓度）和松质骨芯片组成。

Used as a bone graft material in fusion applications, the OsteoStrand Plus C features improved graft packability relative to non-chip containing options – for a denser fill and to ensure minimal graft displacement. Additionally, Orthofix is announcing the launch of the M6-C™ Single-Use, Disposable Instrumentation sets, the first FDA-cleared, single-use, disposable instruments designed specifically for cervical disc arthroplasty..

OsteoStrand Plus C用作融合应用中的骨移植材料，相对于不含芯片的选项，其具有改善的移植物可包装性-用于更密集的填充并确保最小的移植物移位。此外，Orthofix宣布推出M6-C™一次性器械组，这是第一款FDA批准的一次性器械，专门用于颈椎间盘置换术。。

Orthofix Sponsored Events

Orthofix赞助的活动

Orthofix will be sponsoring opportunities to learn more about the 7D FLASH™ Navigation System through an educational dinner with Dr. Jason McGowan and Dr. Amir Vokshoor. Additionally, the company is offering an educational dinner for surgeons to learn more about optimizing fusion through identifying the right combination of interbody surface technology, data-driven biologics, and bone growth therapies with Dr.

Orthofix将通过与Jason McGowan博士和Amir Vokshoor博士的教育晚宴，赞助更多了解7D FLASH™导航系统的机会。此外，该公司还为外科医生提供了一顿教育晚餐，通过确定椎间表面技术、数据驱动生物制剂和骨生长疗法与Dr的正确组合，进一步了解优化融合的方法。

Raymond Hah and Dr. James Bruffey..

Raymond Hah和James Bruffey博士。。

Those attending NASS can learn more about these events and Orthofix’s portfolio of spine solutions by visiting booth #3017.

参加NASS的人可以通过访问booth#3017了解更多有关这些活动和Orthofix脊柱解决方案的信息。

About Orthofix

关于Orthofix

Orthofix is a global medical technology company headquartered in Lewisville, Texas. By providing medical technologies that heal musculoskeletal pathologies, we deliver exceptional experiences and life-changing solutions to patients around the world. Orthofix offers a comprehensive portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including the 7D FLASH™ Navigation System.

Orthofix是一家全球医疗技术公司，总部位于德克萨斯州路易斯维尔。通过提供治疗肌肉骨骼疾病的医疗技术，我们为世界各地的患者提供了非凡的体验和改变生活的解决方案。Orthofix提供全面的脊柱硬件、骨骼生长疗法、专业骨科解决方案、生物制剂和支持技术组合，包括7D FLASH™导航系统。

To learn more, visit Orthofix.com and follow Orthofix on LinkedIn..

要了解更多信息，请访问Orthofix.com并在LinkedIn上关注Orthofix。。

Forward-Looking Statements

前瞻性声明

This news release may include forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” “continue” or other comparable terminology.

本新闻稿可能包括经修订的《1934年证券交易法》第21E节和经修订的《1933年证券法》第27A节所指的前瞻性声明。在某些情况下，您可以通过术语来识别前瞻性陈述，例如“可能”、“将”、“应该”、“预期”、“计划”、“预期”、“相信”、“估计”、“项目”、“打算”、“预测”、“潜力”、“继续”或其他类似术语。

Orthofix cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Each forward-looking statement contained in this news release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.

Orthofix提醒您，本新闻稿中包含的声明不是对历史事实的描述，而是基于公司当前预期和假设的前瞻性声明。本新闻稿中包含的每一项前瞻性声明都存在风险和不确定性，这些风险和不确定性可能导致实际结果与该声明中明示或暗示的结果产生重大差异。

Applicable risks and uncertainties include, among others: the ability of newly launched products to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of robust clinical validation; and the risks identified under the heading “Risk Factors” in Orthofix Medical Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the Securities and Exchange Commission (SEC) on March 5, 2024, as well as any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K filed with the SEC.

适用的风险和不确定性包括：新推出的产品能够按照设计和预期执行，并满足外科医生和患者的需求，包括由于缺乏强有力的临床验证；以及Orthofix Medical Inc.截至2023年12月31日财年的10-K表年度报告中“风险因素”标题下确定的风险，该报告于2024年3月5日提交给证券交易委员会（SEC），以及随后提交给SEC的10-Q表季度报告或8-K表当前报告。

The Company’s public filings with the SEC are available at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Orthofix does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circums.

该公司向美国证券交易委员会提交的公开文件可在www.SEC.gov上查阅。请注意不要过度依赖前瞻性声明，因为前瞻性声明仅在发布之日起生效。Orthofix不打算修改或更新本新闻稿中提出的任何前瞻性声明，以反映事件或情况。